Can Zhu, Zimo Yang, Yuxiao Zhang, Zhenjun Li, Guangchen Li, Bing Yang, Na Kang, Jingwen Wang, Yonghui Sun, Ning Ding*, Yu Rao*, Wanli Liu*,Cell Discovery,2024 Aug 6;10(1):82

Wang X, Song Y, Chen W, Ding N, Liu W, Xie Y, Wang Y, Zhu J, Zeng C. Germline variants of DNA repair genes in early onset mantle cell lymphoma.,Oncogene,40(3):551-563

Ye Y, Ding N, Mi L, Shi Y, Liu W, Song Y, Shu S, Zhu J. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.,Exp Hematol Oncol,10(1):9

Li M, Ding N, Mi L, Shi Y, Du X, Yi Y, Yang L, Liu W, Zhu J. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.,Leuk Lymphoma,63(3):608-617

Yu H, Wang X, Li J, Ye Y, Wang D, Fang W, Mi L, Ding N, Wang X, Song Y, Zhu J. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.,Mol Ther Oncolytics,21:158-170

淋巴瘤临床转化研究

ITK抑制剂逆转复发难治外周T细胞淋巴瘤患者T细胞耗竭的机制研究, 课题负责人, 2025.1.1～2028.12.31, 国家自然科学基金

智能PROTAC脂质纳米药物抗肿瘤效果及生物安全性评估, 课题负责人, 2022.10.1～2026.10.31, 北京市自然科学基金重点研究专项

PAK1诱导套细胞淋巴瘤发生伊布替尼耐药的分子机制研究, 课题负责人, 2020.1.1～2023.12.31, 国家自然科学基金

Itk抑制剂CPI-818联合CD19-CAR-T抗B细胞淋巴瘤的临床前研究, 课题负责人, 2023.12.1～2024.12.31, 横向课题

套细胞淋巴瘤发生依鲁替尼耐药的分子作用机制及相关治疗策略研究, 课题负责人, 2017.1.1～2019.12.31, 北京市自然科学基金